What Happened?
Cambridge, MA-based Korro-Bio Appointed Vineet Agarwal as Chief Financial Officer
About the Company
Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.
About the Person
Vineet Agarwal is Chief Financial Officer at Korro Bio. Previously, Vineet held various senior HR leadership roles in the industry.
Info Source
News
Short Profile